Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMD-477 for Copanlisib-Induced Hyperglycemia in Lymphoma
NCT04253223Phase 1Terminated
- Sponsor
- Duke University
- Start
- Apr 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of volagidemab in hyperglycemia, sponsored by Duke University. Primary endpoints: Adverse Events at 22 days, Serious Adverse Events at 22 days and 4 more. Started Apr 2020; status: terminated.
02
Drugs
volagidemab
03
Conditions
hyperglycemia
Beyond the preview
Go deeper on NCT04253223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04253223.